About Epirus Biopharmaceuticals (NASDAQ:EPRS)
EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:EPRS
- CUSIP: N/A
- Web: www.epirusbiopharma.com
- 50 Day Moving Avg: $0.33
- 200 Day Moving Avg: $1.83
- 52 Week Range: $0.08 - $6.76
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.31
- P/E Growth: 0.00
- Net Margins: -2,025.65%
- Return on Equity: -208.66%
- Return on Assets: -97.67%
- Average Volume: 2.77 million shs.
- Beta: 2.52
Frequently Asked Questions for Epirus Biopharmaceuticals (NASDAQ:EPRS)
What is Epirus Biopharmaceuticals' stock symbol?
Epirus Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EPRS."
How were Epirus Biopharmaceuticals' earnings last quarter?
Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) issued its quarterly earnings data on Tuesday, March, 15th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.07. Epirus Biopharmaceuticals had a negative net margin of 2,025.65% and a negative return on equity of 208.66%. View Epirus Biopharmaceuticals' Earnings History.
Who are some of Epirus Biopharmaceuticals' key competitors?
Some companies that are related to Epirus Biopharmaceuticals include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), ProMetic Life Sciences (PLI), Theratechnologies (TH), Mirati Therapeutics (MRTX), SIGA Technologies (SIGA), Anavex Life Sciences Corp. (AVXL), XOMA Corporation (XOMA), Osiris Therapeutics (OSIR), VBI Vaccines (VBIV), Protalix Biotherapeutics (PLX), Trillium Therapeutics (TRIL), ContraFect Corporation (CFRX), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), Concordia International Corp (CXR) and Can Fite Biopharma Ltd (CANF).
Who are Epirus Biopharmaceuticals' key executives?
Epirus Biopharmaceuticals' management team includes the folowing people:
- Robert Ticktin, Senior Vice President, General Counsel, Secretary
- Vincent E. Aurentz, Chief Business Officer
How do I buy Epirus Biopharmaceuticals stock?
Shares of Epirus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epirus Biopharmaceuticals' stock price today?
MarketBeat Community Rating for Epirus Biopharmaceuticals (NASDAQ EPRS)MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Epirus Biopharmaceuticals stock can currently be purchased for approximately $0.15.
Earnings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)Earnings History by Quarter for Epirus Biopharmaceuticals (NASDAQ EPRS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/9/2014||Q114||$0.20||($0.15)||$9.00 million||$1.60 million||View||N/A|
|8/1/2013||Q2 2013||($0.07)||($0.08)||$2.91 million||$3.89 million||View||N/A|
|5/2/2013||Q1 2013||($0.07)||($0.06)||$3.44 million||$3.70 million||View||N/A|
|3/6/2013||Q4 2012||($0.08)||($0.06)||$3.12 million||$3.67 million||View||N/A|
Earnings Estimates for Epirus Biopharmaceuticals (NASDAQ:EPRS)
2017 EPS Consensus Estimate: ($0.50)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Epirus Biopharmaceuticals (NASDAQ:EPRS)Insider Trades by Quarter for Epirus Biopharmaceuticals (NASDAQ:EPRS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/21/2015||Robert Ticktin||General Counsel||Buy||3,000||$3.72||$11,160.00|| |
|12/17/2015||Aurentz Vincent||Insider||Buy||2,200||$3.43||$7,546.00|| |
|12/16/2015||Amit Munshi||CEO||Buy||8,270||$2.80||$23,156.00|| |
|12/15/2015||Amit Munshi||CEO||Buy||8,069||$2.87||$23,158.03|| |
|12/9/2015||Amit Munshi||CEO||Buy||13,190||$4.07||$53,683.30|| |
|12/9/2015||Aurentz Vincent||Insider||Buy||2,800||$3.85||$10,780.00|| |
|9/21/2015||Amit Munshi||CEO||Buy||10,000||$6.19||$61,900.00|| |
|9/18/2015||Amit Munshi||CEO||Buy||10,000||$5.99||$59,900.00|| |
|2/6/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||167,316||$5.00||$836,580.00|| |
|2/4/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||52,684||$4.98||$262,366.32|| |
|2/4/2015||Scott M Rocklage||Director||Buy||400,000||$5.00||$2,000,000.00|| |
|1/26/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||38,516||$6.47||$249,198.52|| |
|1/23/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||22,530||$6.29||$141,713.70|| |
Headline Trends for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Latest Headlines for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Loading headlines, please wait.
Epirus Biopharmaceuticals (EPRS) Chart for Monday, October, 23, 2017